Abstract

SARS-CoV-2 neuroinvasive and neurotropic abilities may underlie delirium onset and neuropsychiatric outcomes. Only a limited number of studies have addressed the potential effect of SARS-CoV-2 infection on mental health so far. Most studies mainly reported the acute onset of mixed neuropsychiatric conditions in patients infected with SARS-CoV-2, characterized by agitated behavior, altered level of consciousness, and disorganized thinking, regardless of psychological or socioeconomic triggering factors. The present narrative review aims to analyze and discuss the mechanisms underlying the neuroinvasive/neurotropic properties of SARS-CoV-2 and the subsequent mental complications. Delirium appeared as a clinical manifestation of SARS-CoV-2 brain infection in some patients, without systemic or multiple organ failure symptoms. A small number of studies demonstrated that neuropsychiatric symptoms associated with COVID-19, initially presenting as a confused state, may subsequently evolve in a way that is consistent with the patients’ neuropsychiatric history. A literature analysis on this topic prevalently showed case reports and case series of patients presenting delirium or delirium-like symptoms as the main outburst of COVID-19, plus a cognitive impairment, from mild to severe, which pre-existed or was demonstrated during the acute phase or after infection. Dementia appeared as one of the most frequent predisposing factors to SARS-CoV-2 infection complicated with delirium. Instead, contrasting data emerged on the potential link between COVID-19 and delirium in patients with cognitive impairment and without a neuropsychiatric history. Therefore, clinicians should contemplate the possibility that COVID-19 appears as delirium followed by a psychiatric exacerbation, even without other systemic symptoms. In addition, cognitive impairment might act as a predisposing factor for COVID-19 in patients with delirium.

Highlights

  • A cytokine profile resembling HLH is associated with COVID-19. It is characterized by increased plasma concentrations of interleukin (IL)-2, IL-7, granulocyte colony-stimulating factor (G-cerebrospinal fluid (CSF)), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1-α (MIP-1α), and tumor necrosis factor-α (TNF-α) [52]

  • Several studies highlighted that a new mental disease episode might represent a clinical manifestation of COVID-19 sequelae, especially for patients with a psychiatric history

  • Other studies emphasized that delirium may be the sole clinical manifestation of SARS-CoV-2 infection associated with the spread of the virus throughout the central nervous system (CNS) in patients without a psychiatric history

Read more

Summary

A Narrative Review

Michele Fabrazzo 1, * , Antonio Russo 2 , Alessio Camerlengo 1 , Claudia Tucci 1 , Mario Luciano 1 , Valeria De Santis 1 , Francesco Perris 1 , Francesco Catapano 1 and Nicola Coppola 2.

Introduction
Neuroinvasive and Neurotropic Potential of SARS-CoV-2
The Cytokine Storm and Neuroinflammation
Hypoxia as a Triggering Factor of Blood–Brain barrier Disruption
SARS-CoV-2 Infection and Psychiatric Outcomes
Delirium as the Clinical Onset of SARS-CoV-2 Infection
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call